secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001193125-22-216798
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology reports Q2 2022 net income of $174.1M, cash runway through 2026 after Taiho deal
--------------------------------------------------------------------------------

- Cash and investments $656M as of June 30, 2022; expected to fund operations through 2026.
- Completed strategic collaboration with Taiho for CLN-081; received $275M upfront, eligible for $130M milestones.
- Net income of $174.1M in Q2 2022 vs net loss of $12.9M in Q1 2022, driven by $276.8M gain on sale of Cullinan Pearl.
- Updated CLN-081 data at ASCO: median DOR >21 months, median PFS 12 months, 41% confirmed ORR at 100mg BID.
- Initial clinical data for CLN-619 and CLN-049 expected by mid-2023; IND filings for CLN-617, CLN-978 in H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522216798/0001193125-22-216798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522216798/d369450d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-216798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer